Pearson to Step Down as Valeant CEO, Bill Ackman Added to Board
Valeant Pharmaceuticals International Inc.’s (VRX) CEO, Mike Pearson, will step down in a shakeup of the company’s board and management. The move comes after a series of controversies that led to a 61%...
View ArticlePfizer, Allergan Deal is the First Casualty of U.S. Tax Rule Changes
TOKYO – MAY 11: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849. If you were...
View Article3 Cancer Drug Developers to Watch in the Second-half of the Year
Cancer therapies are being released in swarms, and global spending on cancer medicines reached $107 billion last year. Estimates have this figure increasing to $150 billion by 2020, leading to many...
View Article2 Bargain Healthcare Stocks to Buy
Healthcare stocks have taken a beating this year, but there are still bargains to be had. These two stocks may be ready to make a comeback: 1. Valeant Pharmaceuticals (VRX) Valeant’s stock is down...
View Article4 Figures Investors Need to Know From Johnson & Johnsons Q2 Earnings Report
Johnson & Johnson (JNJ) released their Q2 earnings report earlier in the week last week, and investors in the company will need to take a close look at these figures to better understand the...
View Article2 Pharma Stocks Rally on Monday Following Pfizer Deal
Pfizer’s (PFE) announcement that the company will purchase Medivation (MDVN) in a deal worth $14 billion acquisition caused the IBB, the largest Nasdaq biotech ETF, to jump 2% on the day. The...
View ArticlePfizer to Pull Out of Adelaide by 2021
Pharmaceutical giant Pfizer announced that it will close its manufacturing plant in Adelaide, Australia by the end of 2021. The announcement came despite plans being announced less than 12 months ago...
View ArticleHere is why Abbott Laboratories (NYSE:ABT) Is Spending $5.8 Billion For Alere
Abbott Laboratories (NYSE:ABT) agreed to pay $56 a share to acquire Alere Inc. (NYSE:ALR). Alternatively, it would be paying approximately $5.8 billion. The obvious reason is to establish its...
View Article2 Big Pharma Stocks to Buy on the Cheap
The pharmaceutical industry is down even further than the energy sector in 2016, with several big pharma stocks trading low compared to their forward earnings. Two stocks that are trading far lower...
View Article3 Stocks to Watch Out For This Week
3 Stocks to Watch Out For This Week Markets are experiencing political upheavals this week. Global stock markets are patiently waiting for next move from Trump. With increasing crude oil inventory...
View ArticleHere is why Abbott Laboratories (NYSE:ABT) Is Spending $5.8 Billion For Alere
Abbott Laboratories (NYSE:ABT) agreed to pay $56 a share to acquire Alere Inc. (NYSE:ALR). Alternatively, it would be paying approximately $5.8 billion. The obvious reason is to establish its...
View ArticlePearson to Step Down as Valeant CEO, Bill Ackman Added to Board
Valeant Pharmaceuticals International Inc.’s (VRX) CEO, Mike Pearson, will step down in a shakeup of the company’s board and management. The move comes after a series of controversies that led to a 61%...
View ArticlePfizer, Allergan Deal is the First Casualty of U.S. Tax Rule Changes
TOKYO – MAY 11: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849. If you were...
View Article2 Big Pharma Stocks to Buy on the Cheap
The pharmaceutical industry is down even further than the energy sector in 2016, with several big pharma stocks trading low compared to their forward earnings. Two stocks that are trading far lower...
View Article3 Cancer Drug Developers to Watch in the Second-half of the Year
Cancer therapies are being released in swarms, and global spending on cancer medicines reached $107 billion last year. Estimates have this figure increasing to $150 billion by 2020, leading to many...
View Article2 Bargain Healthcare Stocks to Buy
Healthcare stocks have taken a beating this year, but there are still bargains to be had. These two stocks may be ready to make a comeback: 1. Valeant Pharmaceuticals (VRX) Valeant’s stock is down...
View Article4 Figures Investors Need to Know From Johnson & Johnsons Q2 Earnings Report
Johnson & Johnson (JNJ) released their Q2 earnings report earlier in the week last week, and investors in the company will need to take a close look at these figures to better understand the...
View Article2 Pharma Stocks Rally on Monday Following Pfizer Deal
Pfizer’s (PFE) announcement that the company will purchase Medivation (MDVN) in a deal worth $14 billion acquisition caused the IBB, the largest Nasdaq biotech ETF, to jump 2% on the day. The...
View Article3 Stocks to Watch Out For This Week
3 Stocks to Watch Out For This Week Markets are experiencing political upheavals this week. Global stock markets are patiently waiting for next move from Trump. With increasing crude oil inventory...
View ArticlePfizer to Pull Out of Adelaide by 2021
Pharmaceutical giant Pfizer announced that it will close its manufacturing plant in Adelaide, Australia by the end of 2021. The announcement came despite plans being announced less than 12 months ago...
View Article
More Pages to Explore .....